KRAS mutation in pancreatic cancer

Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene. The KRAS oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Seminars in oncology Ročník 48; číslo 1; s. 10
Hlavní autor: Luo, Ji
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.02.2021
Témata:
Humans
Mutation
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - genetics
Proto-Oncogene Proteins p21(ras) - genetics
Signal Transduction - genetics
MAPK pathway
G12C
KRAS
Targeted therapy
Pancreatic cancer
ISSN:1532-8708, 1532-8708
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene. The KRAS oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network represents a major target for therapeutic intervention. A number of inhibitors have been developed against kinase effectors in various Ras signaling pathways. Their clinical activity, however, has been disappointing thus far. More recently, covalent inhibitors targeting the KRAS oncoprotein have been developed. These inhibitors showed promising activity in KRAS mutant pancreatic cancer in early clinical trials. This review will present an updated summary of our understanding of mutant KRAS function in pancreatic cancer and discuss therapeutic strategies that target oncogenic KRAS signaling in this disease.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1532-8708
1532-8708
DOI:10.1053/j.seminoncol.2021.02.003